XML 70 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Shareholders' equity
12 Months Ended
Dec. 31, 2019
Shareholders' equity  
Shareholders' equity

Note 19 – Shareholders’ equity

(a)

Share capital

The Company’s authorized capital stock includes an unlimited number of common shares (189,381,388 common shares issued and outstanding as at December 31, 2019) having no par value and preferred shares issuable in series (issued - nil).

Changes in share capital in the year ended December 31, 2019 and year ended December 31, 2018 were as follows:

 

 

 

 

 

 

 

 

 

 

 

Number

 

 

 

 

 

  

  

of shares

  

  

Amount

 

Balance at January 1, 2018

 

 

185,930,331

 

$

5,107.8

 

Exercise of stock options

 

 

94,018

 

 

5.5

 

Vesting of restricted share units

 

 

52,882

 

 

3.3

 

Dividend reinvestment plan (Note 15(c))

 

 

615,250

 

 

41.7

 

Balance at December 31, 2018

 

 

186,692,481

 

$

5,158.3

 

At-the-market equity offering (Note 15(b))

 

 

1,433,400

 

 

136.0

 

Acquisition of Salares Norte (Note 3(e))

 

 

366,499

 

 

27.0

 

Exercise of stock options

 

 

283,863

 

 

17.3

 

Vesting of restricted share units

 

 

46,375

 

 

3.3

 

Dividend reinvestment plan (Note 15(c))

 

 

558,770

 

 

48.8

 

Balance at December 31, 2019

 

 

189,381,388

 

$

5,390.7

 

 

(b)

At-the-Market Equity Program

On July 19, 2019, the Company established an at-the-market equity program (the “ATM Program”) whereby the Company is permitted to issue up to an aggregate of $200 million worth of common shares from treasury at prevailing market prices to the public through the Toronto Stock Exchange, the New York Stock Exchange or any other marketplace on which the common shares are listed, quoted or otherwise trade. The volume and timing of distributions under the ATM Program is determined at the Company’s sole discretion, subject to applicable regulatory limitations and blackout periods. The ATM Program is effective until July 18, 2020, unless terminated prior to such date by the Company.

During the year ended December 31, 2019, the Company issued 1,433,400 common shares at an average price per common share of $96.56. The gross proceeds to the Company from these issuances were $138.4 million, and the net proceeds were $136.0 million after deducting agent commission costs of $1.4 million and other share issuance costs of $1.0 million.

(c)

Dividends

In 2019, the Company declared dividends of $0.99 per common share (2018  - $0.95 per common share). 

Dividends paid in cash and through the Company’s Dividend Reinvestment Plan (“DRIP”) were as follows:

 

 

 

 

 

 

 

 

 

 

 

  

  

2019

  

  

2018

  

Cash dividends

 

 

$

138.2

 

 

$

136.1

 

DRIP dividends

 

 

 

48.8

 

 

 

41.7

 

 

 

 

$

187.0

 

 

$

177.8

 

(d)

Stock-based payments

On March 7, 2018, the Company’s Board of Directors adopted an amended and restated share compensation plan covering both stock options and RSUs effective May 9, 2018 (the “Plan”). Pursuant to the Plan, the Company may grant incentive stock options to directors, officers, employees and consultants at the discretion of the Board of Directors.  The exercise price and vesting period of any option is fixed by the Board of Directors on the date of grant.  The term of options is at the sole discretion of the Board of Directors but may not exceed ten years from the date of grant.  Options expire on the earlier of the expiry date or the date of termination and are non-transferable.  The options granted will be adjusted in the event of an amalgamation, rights offering, share consolidation or subdivision or other similar adjustments of the share capital of the Company. The aggregate number of common shares that may be issued under the Plan is limited to 9,700,876 common shares. Within any one-year period, the number of common shares issued to any single insider participant under the Plan shall not exceed 5% of the common shares then issued and outstanding.

Options to purchase common shares of the Company that have been granted in accordance with the Plan and pursuant to other agreements are as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2019

 

 

2018

 

 

  

  

 

    

Weighted

  

  

 

    

Weighted

 

 

 

 

 

 

average exercise

 

 

 

 

average exercise

 

 

 

 

Number

 

price

 

 

Number

 

price

 

Stock options outstanding, beginning of year

 

 

1,015,409

 

C$

69.13

 

 

955,603

 

C$

64.48

 

Granted

 

 

104,881

 

C$

129.32

 

 

153,824

 

C$

92.77

 

Exercised

 

 

(283,863)

 

C$

59

 

 

(94,018)

 

C$

60.49

 

Stock options outstanding, end of the year

 

 

836,427

 

C$

80.01

 

 

1,015,409

 

C$

69.13

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable stock options, end of the year

 

 

596,402

 

C$

68.05

 

 

710,064

 

C$

60.40

 

 

Options granted during the years ended December 31, 2019 and 2018 have a ten-year term and vest over three years in equal portions on the anniversary of the grant date.  The fair value of stock options was calculated using the Black-Scholes option pricing model based on the following weighted average assumptions, resulting in a fair value of $2.2 million, or a weighted average fair value of C$28.11 per stock option, (2018 — $3.0 million, or C$25.77 per stock option).

 

 

 

 

 

 

 

 

 

 

 

2019

 

 

2018

 

Risk-free interest rate

 

 

1.62

%

 

2.05

%

Expected dividend yield

 

 

1.02

%

 

1.38

%

Expected price volatility of the Company’s common shares

 

 

27.5

%

 

32.7

%

Expected life of the option

 

 

4 years

 

 

5 years

 

Forfeiture rate

 

 

0

%

 

0

%

 

During the year ended December 31, 2019, an expense of $2.3 million (2018 - $2.6 million) related to stock options has been included in the consolidated statement of income and other comprehensive income, and $0.5 million (2018 - $0.4 million), was capitalized to royalty, stream and working interest, net, respectively. As at December 31, 2019, there was $3.5 million (2018 – $3.9 million) of total unrecognized non-cash stock-based compensation relating to stock options granted under the Plan, which is expected to be recognized over a weighted average period of 1.7 years (2018 – 1.7 years).

Options to purchase common shares outstanding at December 31, 2019, exercise prices and weighted average lives to maturity as follows:

 

 

 

 

 

 

 

 

 

 

 

    

 

    

 

    

Weighted

 

 

Exercise

 

Options

 

Options

 

average life

 

 

price

 

outstanding

 

exercisable

 

(years)

 

 

C$33.12

 

1,500

 

1,500

 

0.90

 

 

C$40.87

 

38,076

 

38,076

 

3.95

 

 

C$42.43

 

2,000

 

2,000

 

2.25

 

 

C$46.17

 

90,000

 

90,000

 

3.63

 

 

C$55.58

 

27,397

 

27,397

 

2.95

 

 

C$58.67

 

35,000

 

35,000

 

5.64

 

 

C$59.52

 

53,376

 

53,376

 

4.95

 

 

C$65.76

 

65,258

 

65,258

 

5.95

 

 

C$75.45

 

178,936

 

178,936

 

6.95

 

 

C$88.76

 

45,082

 

13,261

 

8.64

 

 

C$94.57

 

98,562

 

27,835

 

8.95

 

 

C$100.10

 

96,359

 

63,763

 

7.95

 

 

C$129.32

 

104,881

 

 —

 

9.95

 

 

 

    

836,427

    

596,402

    

6.86

 

 

(e)

Restricted share units

During the year ended December 31, 2019, 20,153 performance-based RSUs (2018 – 24,724) and 19,863 time-based RSUs (2018 – 24,341) were awarded to management of the Company. The fair value of the RSUs, which is determined with reference to the weighted average trading price of the Company’s common shares over the five trading days immediately preceding the date of issuance, was determined to be $3.9 million in 2019 (2018 - $3.4 million). Included in the Company’s stock-based compensation expense is an amount of $2.6 million (2018 – $2.6 million) relating to RSUs. In addition, $0.6  million related to the RSUs was capitalized to royalty, stream and working interest, net (2018 – $0.5 million). As at December 31, 2019, there is $6.4 million (2018 – $5.4 million) of total unrecognized non-cash stock-based compensation expense relating to non-vested restricted share units granted under the Plan, which is expected to be recognized over a weighted average period of 2.1 years (2018 – 2.1 years).

(f)

Deferred Share Unit Plan

During the year ended December 31, 2019, 18,448 DSUs and dividend equivalent DSUs were granted to directors under the DSU Plan (2018 – 18,420), and no DSUs and dividend equivalent DSUs were redeemed (2018 - 15,298). The value of the DSU liability as at December 31, 2019 was $10.8 million (2018 - $6.1 million). The mark-to-market adjustment recorded for the year ended December 31, 2019 in respect of the DSU Plan, resulted in a loss of $2.8 million (2018 – gain of $0.3 million).

(g)

Outstanding Stock Options and Restricted Share Units

The following table sets out the maximum shares that would be outstanding if all of the stock options and RSUs at December 31, 2019 and 2018 were exercised:

 

 

 

 

 

 

 

 

 

  

  

2019

  

  

2018

 

Common shares outstanding

 

 

189,381,388

 

 

186,692,481

 

Stock options

 

 

836,427

 

 

1,015,409

 

Restricted Share Units

 

 

108,978

 

 

115,337

 

 

 

 

190,326,793

 

 

187,823,227